AssetMark Inc
AKBA icon

AssetMark Inc’s Akebia Therapeutics AKBA Stock Holding History

AssetMark Inc’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-45
Closed – – 1331
2018
Q4 		$0 Hold
45
– – ﹤0.01% 1419
2018
Q3 		$0 Sell
45
-10
-18% -$89 ﹤0.01% 1397
2018
Q2 		$1K Hold
55
– – ﹤0.01% 1312
2018
Q1 		$1K Buy
55
+16
+41% +$224 ﹤0.01% 1312
2017
Q4 		$1K Buy
+39
New +$647 ﹤0.01% 1540

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

AssetMark Inc's AKBA Position: Q1 2019 in Review

AssetMark Inc sold out of Akebia Therapeutics (AKBA) in Q1 2019, closing a stake of 45 shares.

AssetMark Inc first reported a position in AKBA in Q4 2017 and held it in 5 quarters. The position peaked at $1K in Q2 2018. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

  • AssetMark Inc reported no remaining Akebia Therapeutics position as of Q1 2019 after selling out during the quarter.
  • AssetMark Inc sold 45 Akebia Therapeutics shares in Q1 2019.
  • AssetMark Inc first reported a position in Akebia Therapeutics in Q4 2017 and held it in 5 quarters.
  • AssetMark Inc's Akebia Therapeutics position peaked at $1K in Q2 2018.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on AssetMark Inc's 13F filing for Q1 2019, filed 14 May 2019.